Business
Aptar Pharma Announces New Patent Applications and Preclinical Data Supporting Investigation of Intranasal and Pulmonary GLP-1 Delivery
CRYSTAL LAKE, Ill., May 28, 2026--Aptar Pharma announces patent applications and preclinical data supporting investigational intranasal and pulmonary GLP-1 delivery.
About this update from Aptargroup, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":886,"height":316,"url":"https://media.zenfs.com/en/business-wire.com/414e7f5659f352c02a4e477bc943d755"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.oQDLULBpOfydpgSt_pYBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0Mg--/https://media.zenfs.com/en/business-wire.com/414e7f5659f352c02a4e477bc943d755","width":886,"height":316},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/4.DRtsX0PuR_YYkxLnj6hQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIyOA--/https://media.zenfs.com/en/business-wire.com/414e7f5659f352c02a4e477bc943d755","width":640,"height":228},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/azNIJ7xwespYaFC9Knpj4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE3NzI7aD02MzI-/https://media.zenfs.com/en/business-wire.com/414e7f5659f352c02a4e477bc943d755","width":886,"height":316}},"lazy":false},{"type":"text","content":"Program expands Aptar Pharma’s capabilities to support inhaled and intranasal delivery of biologics","length":99,"tagName":"p","attribs":{}},{"type":"text","content":"CRYSTAL LAKE, Ill., May 28, 2026--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced the publication of three new international patent applications focused on enabling inhaled and nasal delivery of GLP‑1‑based therapies. The applications arise from an internal strategic R&D program intended to expand Aptar Pharma’s capabilities in biologics delivery and strengthen its intellectual property position in high-growth therapeutic areas.","length":515,"tagName":"p"},{"type":"text","content":"Pulmonary and respiratory delivery is expanding beyond traditional allergy and asthma applications, with growing interest in broader systemic drug delivery. The newly published patent applications describe formulation approaches for GLP‑1 drug substances, including spray‑dried and powder processing technologies designed to support nasal and pulmonary administration. Preclinical pharmacokinetic (PK) studies were performed on both liquid and powder formulations of semaglutide, showing up to 10x improvement in the systemic Cmax (peak blood concentration) when compared with a comparable oral dose in a preclinical model. Together, the published patent applications and supporting pr...